Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4OQRD)

Drug Name

HIF-1alpha Drug Info

Synonyms

Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; UNII-NA856793UT; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 4	[1]

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID: 5328127
ChEBI ID: CHEMBL299763
CAS Number: CAS 192705-79-6
TTD Drug ID: DM4OQRD

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Fibroblast growth factor receptor (FGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erdafitinib	DMI782S	Bladder cancer	2C94	Approved	[4]
Futibatinib	DMWM4D0	Intrahepatic cholangiocarcinoma	2C12.10	Approved	[5]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[6]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[6]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[6]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
BAY1163877	DMCSGJ2	Bladder cancer	2C94	Phase 2	[8]
ICP-192	DM524GR	Bladder cancer	2C94	Phase 2	[9]
PRN1371	DMR7BAO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
PD173074	DMP0N4U	Nasopharyngeal carcinoma	2B6B	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Hypoxia-inducible factor 1 alpha (HIF-1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IT-101	DMNDGWE	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
2-Methoxyestradiol	DMGBPME	Pulmonary arterial hypertension	BB01.0	Phase 2	[11]
PX-478	DM4AU8K	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
EZN-2968	DM2NBC7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
ENMD-1198	DM9BJ3G	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
Pyrrolidine carboxamide derivative 1	DMJK98Z	N. A.	N. A.	Patented	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor (FGFR)	TT0LF7H	NOUNIPROTAC	Antagonist	[2]
Hypoxia-inducible factor 1 alpha (HIF-1A)	TTQHWNA	HIF1A_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00880672) Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate. U.S. National Institutes of Health.
2	Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
3	A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5	TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
8	Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
9	Clinical pipeline report, company report or official report of InnoCare Pharma.
10	CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67.
11	2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squam... Clin Cancer Res. 2004 Dec 15;10(24):8665-73.
12	The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr;8(4):947-58.
13	Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1), in patients with refractory solid tumors.Cancer Chemother Pharmacol.2014 Feb;73(2):343-8.
14	ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.
15	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22.